

FIRST HALF F19

REVENUE



Blackmores achieves record half year revenue of \$319 million



Overall revenue growth to Chinese consumers estimated at 8%



Strong revenue growth in ANZ up 19%. Additional brand investment is driving sales

个个 Asia

Korea up 67%, Hong Kong up 39%, Taiwan up 150%, Indonesia up 72%

PROFIT

\$34m

Net profit for the half year, in line with prior corresponding period

1268%

Increase in Other Asia segment EBIT

MARKET SHARE

No.1

Blackmores remains #1 brand in Australia with 16.7% market share¹

EFFICIENCY

Business Improvement Program established to target \$60m of savings over 3 years

AUSTRALIA & NEW ZEALAND

BLACKMORES

- Revenue of \$144 million up \$23 million or 19%
- Number one VDS brand in Australia with 16.7% market share¹
- Continued significant investment in A&P is delivering sales results
- Completed acquisition of Impromy evidencebased weight management program developed with CSIRO
- PAW revenue growth of 21% year-on-year
- Australian retailers are targeting export trade
- Overall domestic sales growth ~ 6%



- ASIA: CHINA
- China segment sales were down 11% in the half compared to the pcp to \$65m, although when China-influenced sales through Australian retailers are taken into account, we estimate growth in sales to Chinese consumers to be around 8%
- Contributing to this China result was a channel shift with Australian retailers more directly targeting the China export trade, which has benefited our ANZ segment results
- This channel shift was highlighted in quarter one and has continued to accelerate through quarter two
- New China Country Manager, Sophia Tseng, appointed commencing later this month



BLACKMORES

ASIA

- Across Asia we recorded strong levels of revenue growth in a number of markets
 - Korea +67%, Taiwan +150%, Hong Kong +39%
 - Indonesia continuing to grow strongly +72%, driven by entry into Indonesia's largest pharmacy retail chain, Kimia Farma
- Other Asia segment revenue up 34% pcp to \$53m
- Other Asia EBIT up 268% during the half, due to three key factors:
 - 1. Success of NPD and marketing programs
 - 2. Distribution and retailer expansion
 - 3. Improved supply environment



BIOCEUTICALS GROUP

BLACKMORES'

- BioCeuticals Group continues to lead the practitioner category with revenue growth of 7%
- Category leadership driven by education, specialist products and innovation
- Growth in pharmacy channel
- Successful NPD launches
 - Range extension for ArmaForce and Ultra Muscleze
- Expansion into clinical services
- Commenced a medicinal cannabis trial for glioblastoma multiform, a form of brain cancer. Trial run in conjunction with Prince of Wales Hospital and Endeavour College of Natural Therapies.



PROFIT & LOSS

- Record revenue of \$319m, up 11%*
- Gross margin improvement impacted by raw material price increases and higher rebates related to stock clearance and channel mix
- Significant investment in selling and marketing expenses, particularly in China
- Operating expenses growth reflects investments across Asia and in Group capability and strategic initiatives (e.g. technology and capability programs)
- NPAT of \$34m flat as a result of the planned increased investment

A\$m	H1 FY19	H1 FY18	Chg \$	Chg %
Sales Revenue	319.4	287.4	32.0	11%
Raw materials and consumables used	124.2	112.4	11.8	11%
% of sales revenue	38.9%	39.1%		
Selling and marketing expenses	32.0	24.5	7.5	31%
Operating expenses	113.8	102.0	11.8	12%
Total Expenses	270.0	238.9	31.1	13%
EBIT	50.5	49.3	1.2	2%
% of sales revenue	15.8%	17.1%		
Net interest expense	2.2	2.0	0.2	8%
Income tax expense	14.1	13.9	0.2	1%
% effective tax rate	29.3%	29.5%		
Non-controlling interest	(0.2)	(0.9)	0.7	(85%)
NPAT	34.3	34.2	0.1	0%
Invoiced sales	397.4	351.9	45.5	13%
Promo and other rebates % of IS	19.6%	18.3%		+1.3ppts

*Compared to prior corresponding period

BALANCE SHEET

- Strong financial health and balance sheet maintained
- No change in receivables risk profile or provisions in the period
- Inventory levels at \$110m, up \$6m* to support sales growth – with higher level of safety stock maintained
- Payables lower reflecting timing of supplier payments
- Goodwill and intangibles of \$77m, up \$11m* largely due to acquisition of Impromy in the period

A\$m	Dec-18	Jun-18	\$ Chg	% Chg
Receivables	138.9	150.8	(11.9)	(8%)
Inventories	110.4	104.0	6.4	6%
Less:				
Trade and other payables	(131.4)	(157.9)	26.5	(17%)
Working Capital	118.0	96.9	21.1	22%
Property, plant and equipment	78.4	76.3	2.1	3%
Goodwill and intangible assets	77.3	66.2	11.1	17%
Other net liabilities	(63.9)	(46.2)	(17.7)	38%
Net Assets	209.8	193.3	16.5	9%
Less:				
Non-controlling interests	(0.2)	(0.4)	0.2	(42%)
Shareholders' Equity	209.5	192.9	16.6	9%
Return on shareholders' equity ¹	16.4%	19.0%		2.6 ppts
Return on assets ²	10.7%	11.8%		(1.1) ppts

¹ Calculated as half-year NPAT attributable to shareholders of Blackmores Limited divided by closing shareholders' equity.

² Calculated as half-year EBIT divided by average total assets

NET DEBT

- Net debt at \$71m increased by \$21m, due to increased working capital and the funding of the Impromy acquisition in November
- Net interest cover at 22.5 times continues to reflect a prudent approach to servicing the Group's interest commitments
- Conservative level of headroom maintained, well supported by a diverse range of facilities and banking partners
- The maturity profile of existing bank loan facilities by calendar year is as follows:

2019 \$55m

2020 \$70m


2021 \$30m

2022 \$65m

 Commenced debt renegotiation in the period which is expected to conclude in the second half

A\$m	Dec 2018	Jun 2018	Chg \$	Chg %
Debt	109.0	86.0	23.0	27%
Cash and cash equivalents	(38.1)	(36.5)	(1.6)	4%
Net debt	70.9	49.5	21.4	43%
Net interest cover (times)	22.5	25.9		
Gearing ratio	25.3%	20.4%		4.9 ppts







OPERATING CASH FLOW

- Cash generated from operations of \$34m, an increase of 22% driven by strong receipts from customers*
- Net cash flows from operating activities of \$15m, an increase of 74% reflecting timing of taxation payments
- Cash conversion ratio (CCR) of 60% up 8 ppts*

A\$m	H1 FY19	H1 FY18	Chg \$	Chg %
Receipts from customers	374.4	318.0	56.4	18%
Payments to suppliers and employees	(340.8)	(290.3)	(50.5)	17%
Cash generated from operations	33.6	27.7	5.9	22%
Interest and other costs of finance paid	(3.1)	(2.8)	(0.3)	10%
Income taxes paid	(15.6)	(16.3)	0.7	(4%)
Net cash flows from operating activities	15.0	8.6	6.4	74%
EBITDA	55.8	53.5	2.3	4%
Cash conversion ratio (CCR) %	60%	52%		+8 ppts





INTERIM DIVIDEND

- EPS of 198.9 cents, broadly in line with pcp
- Interim dividend of 150 cents per share fully franked
- Dividend payout ratio of 75%
- Record date is 5 March 2019
- Payable on 20 March 2019
- Dividend Reinvestment Plan maintained with 2.5% discount

	FY19	FY18	Chg	% Chg
Dividend Paid (cps)				
Interim dividend	150	150	-	0%
Dividend Paid \$m				
Interim dividend	25.9	25.8	0.1	0%
Payout ratio %	75.4%	75.6%		
Franking %	100%	100%		

Dividend per Share (c)



SECOND QUARTER F19




AUD \$m	F19	F18	% vs LY
Revenue	165.4	153.9	+7.5%
EBITDA	28.7	29.2	-1.6%
EBIT	26.0	27.0	-3.7%
Net interest expense	1.2	1.1	+9.7%
Profit before tax	24.8	25.9	-4.3%
Income tax expense	7.0	7.7	-8.6%
NPAT*	17.8	18.7	-4.9%

Q2 RESULTS



NPAT (\$m)



^{*}Profit for the period attributable to the owners of Blackmores Ltd

OUTLOOK

- Our outlook is for modest full-year revenue growth
- China sales in the third quarter impacted by changes to the way consumers purchase our products, higher inventory in the trade and a general softening of consumer sentiment
- As a result, we do not expect the second half profit performance to be ahead of the first half result
- Established Business Improvement Program to target \$60 million of savings over the next three years to fund further investment and deliver margin improvement



QUESTIONS?

